Select Your Region
Americas
Europe
Africa
Global
A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy
- Autoimmune Disorder
- Multiple Sclerosis (MS)
- Clinically Isolated Syndrome (CIS)
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:
Active, not recruiting
This trial runs in
Countries
- France
- Germany
- Spain
- Switzerland
- United States
Trial Identifier:
NCT04998812 2021-000062-14 MN42988
Trial Summary
This study will evaluate the potential placental transfer of ocrelizumab in women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] whose last dose of ocrelizumab was administered any time from 6 months before the last menstrual period (LMP) through to the first trimester (up to gestational week 13) of pregnancy, and the corresponding pharmacodynamic effects (B cell levels) in the infant.
Hoffmann-La Roche
Sponsor
Phase 4
Phase
NCT04998812, MN42988, 2021-000062-14
Trial Identifier
Ocrelizumab
Treatments
Multiple Sclerosis, Clinically Isolated Syndrome
Condition
Official Title
A Phase IV Multicenter, Open-Label Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy
Eligibility Criteria
Female
Gender
≥18 Years & ≤ 40 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Diagnosis of MS or CIS (in line with the locally approved indications)
- Currently pregnant with singleton pregnancy at gestational week ≤30 at enrolment
- Documentation that first and second obstetric ultrasound has been conducted before enrolment during the screening period
- Documentation that the last exposure to ocrelizumab occurred up to 6 months before the LMP before the woman became pregnant OR during the first trimester of pregnancy
Exclusion Criteria
- Last exposure to ocrelizumab >6 months before the woman's LMP or later than the first trimester of pregnancy
- Gestational age at enrolment >30 weeks
- Non-singleton pregnancy
- Received the last dose of ocrelizumab at a different posology other than per the local prescribing information
- Lack of access to ultrasound pre-natal care as part of standard clinical practice
- Prior or current obstetric/gynecological conditions associated with adverse pregnancy outcomes
- Pre-pregnancy body mass index >35 kg/m2
- Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
- Prior or current history of primary or secondary immunodeficiency, or woman in an otherwise severely immunocompromised state
- Significant and uncontrolled disease that may preclude a woman from participating in the study
- Women with known active malignancies or being actively monitored for recurrence of malignancy including solid tumors and hematological malignancies
- Prior or current history of alcohol or drug abuse, or current use of tobacco
- Positive screening tests for hepatitis B
- Treatment with drugs known to have teratogenic effects
- Planned treatment with interferons, glatiramer acetate, or pulsed corticosteroids as a bridging therapy after the last ocrelizumab dose and throughout pregnancy
- Treatment with disease-modifying therapies for MS within their respective half-lives prior to the last ocrelizumab dose or prior to the LMP
- Treatment with natalizumab within 12 weeks prior to the LMP
- Treatment with teriflunomide within the last two years, unless measured plasma concentrations are <0.02 mg/L. If levels are >0.02 mg/L or not known, an accelerated elimination procedure is required
- Treatment with any investigational agent within 6 months or five half-lives of the investigational drug prior to the last ocrelizumab dose or prior to the LMP
For the latest version of this information please go to www.forpatients.roche.com